<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01936129</url>
  </required_header>
  <id_info>
    <org_study_id>R624/45/2008</org_study_id>
    <nct_id>NCT01936129</nct_id>
  </id_info>
  <brief_title>Investigating the Neuroprotective Effect of Cop-1 (Copaxone) in Acute Primary Angle Closure</brief_title>
  <official_title>Investigating the Neuroprotective Effect of Cop-1 in Acute Primary Angle Closure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Singapore Eye Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Singapore Eye Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomised controlled trial to assess the neuroprotective effect of Cop-1&#xD;
      (Copaxone) in patients with acute primary angle closure (APAC). The standardized management&#xD;
      of APAC will include medical therapy to reduce intraocular pressure (IOP), followed by laser&#xD;
      peripheral iridotomy. Cop-1 will be administered in addition to standard therapy as a&#xD;
      subcutaneous dose once within 24 hours of presentation, and then one week later (total 2&#xD;
      injections). The control group will have placebo in addition to standard regimen. Subjects in&#xD;
      the study will have visual field test performed with the Humphrey Visual Field Analyzer II,&#xD;
      retinal nerve fibre layer (RNFL) thickness measured with the Stratus optical coherence&#xD;
      tomography (OCT) and Optic nerve head evaluated with the Heidelberg retinal tomography (HRT).&#xD;
      At least 2 baseline visual field tests will also be performed in the first week. Subsequent&#xD;
      visits will be at week 4, 8, 12 and 16. The outcome criteria will be difference in visual&#xD;
      field, RNFL thickness, and optic nerve head structural changes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aim To assess the neuroprotective effect of Cop-1 (Copaxone) in reducing functional and&#xD;
      structural damage after acute primary angle closure (APAC)&#xD;
&#xD;
      Outcome measures:&#xD;
&#xD;
      The primary outcome measures will be the point-wise linear regression in the visual fields.&#xD;
&#xD;
      The secondary outcome measure will be the evaluation of structural changes, namely, RNFL&#xD;
      thickness and Optic disc changes as measured by stratus OCT and HRT respectively.&#xD;
&#xD;
      Study population&#xD;
&#xD;
      The study population (n=196; 1:1 randomisation) will be patients with APAC attending the&#xD;
      Singapore National Eye Centre who fulfil the inclusion criteria and are willing to take part&#xD;
      in the study.&#xD;
&#xD;
      Study design:&#xD;
&#xD;
      The study design is a randomized, placebo controlled, double blinded trial where patients&#xD;
      with APAC will be randomized to receive either Cop-1 (Copaxone) or placebo in addition to the&#xD;
      standard medical therapy.&#xD;
&#xD;
      An interim analysis will be conducted after 40 patients complete the trial. Routine&#xD;
      examination will be done at all visits.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2010</start_date>
  <primary_completion_date type="Anticipated">October 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual field progression using point-wise linear regression.</measure>
    <time_frame>16 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The secondary outcome measure will be the evaluation of structural changes of the optic nerve head.</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">196</enrollment>
  <condition>Glaucoma, Angle-closure, Primary, Acute</condition>
  <arm_group>
    <arm_group_label>Copaxone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>COPAXONE (glatiramer acetate) will be administered as a subcutaneous dose (20mg) once, one injection no later than 7 days from the initiation of the attack, and 1 more injection administered one week after the first injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (buffered normal saline w/v)will be administered as a subcutaneous dose, one injection no later than 7 days from the initiation of the attack, and 1 more injection administered one week after the first injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Copaxone</intervention_name>
    <arm_group_label>Copaxone</arm_group_label>
    <other_name>Cop 1</other_name>
    <other_name>glatiramer acetate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (buffered normal saline w/v)</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  • patients with APAC who present to the centre not later than 7 days from the&#xD;
             initiation of the attack.&#xD;
&#xD;
               -  the presence of at least two of the following symptoms: ocular or periocular&#xD;
                  pain, nausea or vomiting or both, and an antecedent history of blurring of vision&#xD;
                  with haloes;&#xD;
&#xD;
               -  a presenting intraocular pressure of at least 28 mm Hg on Goldmann applanation&#xD;
                  tonometry;&#xD;
&#xD;
               -  the presence of at least three of the following signs: conjunctival injection,&#xD;
                  corneal epithelial oedema, middilated unreactive pupil, and shallow anterior&#xD;
                  chamber;&#xD;
&#xD;
               -  the presence of an occludable angle in the affected eye on gonioscopy;&#xD;
&#xD;
               -  Age more than 21 years.&#xD;
&#xD;
               -  Informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  • evidence of a prior acute angle closure attack (the presence of iris whorling, focal&#xD;
             iris atrophy, or glaucomflecken with a history of an acute red eye and decreased&#xD;
             vision). This will not include senile iris and sphincter atrophy);&#xD;
&#xD;
               -  Pre-existing chronic angle closure glaucoma in the eye with APAC&#xD;
&#xD;
               -  secondary causes of angle closure like subluxed lens, uveitis, trauma and&#xD;
                  neovascular glaucoma;&#xD;
&#xD;
               -  cataract that is deemed significant enough to require surgery during the course&#xD;
                  of the trial or that makes field testing or optic disc imaging not technically&#xD;
                  possible- visual acuity less than 6/36 due to any type of cataract;&#xD;
&#xD;
               -  corneal abnormalities, media opacities, or retinal abnormalities that would&#xD;
                  affect scanning laser polarimetry;&#xD;
&#xD;
               -  previous intraocular surgery;&#xD;
&#xD;
               -  currently pregnant or nursing women, or women considering pregnancy;&#xD;
&#xD;
               -  Severe health problems precluding follow-up such as end-stage heart disease,&#xD;
                  kidney disease, respiratory disease, or cancer and life expectancy less than one&#xD;
                  year.&#xD;
&#xD;
               -  History of allergy to mannitol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tin Aung, FRCOphth,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Singapore National Eye Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tin Aung, FRCOphth,PhD</last_name>
    <phone>6563224500</phone>
    <email>aung.tin@snec.com.sg</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Monisha E Nongpiur, MD</last_name>
    <phone>6563224500</phone>
    <email>monisha.esther.nongpiur@seri.com.sg</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Singapore Eye Research Institute</name>
      <address>
        <city>Singapore</city>
        <zip>168751</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tin Aung, FRCOphth,PhD</last_name>
      <phone>6563224500</phone>
      <email>aung.tin@snec.com.sg</email>
    </contact>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <study_first_submitted>August 28, 2013</study_first_submitted>
  <study_first_submitted_qc>September 1, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 5, 2013</study_first_posted>
  <last_update_submitted>September 4, 2013</last_update_submitted>
  <last_update_submitted_qc>September 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 6, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Singapore Eye Research Institute</investigator_affiliation>
    <investigator_full_name>Prof Aung Tin</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma, Angle-Closure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glatiramer Acetate</mesh_term>
    <mesh_term>(T,G)-A-L</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

